Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Director departure
CC transcript
|
|
IMMUCOR INC (BLUD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/25/2017 |
15-15D
| Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]: |
| 07/18/2017 |
8-K
| Quarterly results |
| 06/23/2017 |
8-K
| Form 8-K - Current report |
| 06/21/2017 |
8-K
| Form 8-K - Current report |
| 06/19/2017 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/19/2017 |
8-K
| Form 8-K - Current report |
| 04/11/2017 |
10-Q
| Quarterly Report for the period ended February 28, 2017 |
| 01/17/2017 |
10-Q
| Quarterly Report for the period ended November 30, 2016 |
| 10/17/2016 |
10-Q
| Quarterly Report for the period ended August 31, 2016 |
| 08/22/2016 |
10-K
| Annual Report for the period ended May 31, 2016 |
| 05/10/2016 |
8-K
| Form 8-K - Current report |
| 04/11/2016 |
10-Q
| Quarterly Report for the period ended February 29, 2016 |
| 01/13/2016 |
10-Q
| Quarterly Report for the period ended November 30, 2015 |
| 12/15/2015 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/13/2015 |
10-Q
| Quarterly Report for the period ended August 31, 2015 |
| 08/21/2015 |
10-K
| Annual Report for the period ended May 31, 2015 |
| 07/13/2015 |
8-K
| Resignation/termination of a director |
| 07/02/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Jeffrey R. Binder Appointed President and CEO of Immucor Norcross, Georgia – June 29, 2015– Immucor, Inc., a global leader in transfusion and transplantation diagnostics and a portfolio company of global private investment firm TPG, today announced the appointment of Jeffrey R. Binder as President, Chief Executive Officer and Chairman of the Board of Directors. Binder succeeds CEO William A. Hawkins III , who now assumes the role of Lead Director on the Immucor Board of Directors. Binder, a 22-year veteran of the healthcare industry, has proven experience in helping companies realize growth opportunities. Prior to joining Immucor, Binder was the President and CEO of Biomet, a leading designer, manufacturer and marketer of surgical and non-surgical products used primarily by orthopedic surg..." |
|
| 04/10/2015 |
10-Q
| Quarterly Report for the period ended February 28, 2015 |
| 01/13/2015 |
10-Q
| Quarterly Report for the period ended November 30, 2014 |
| 10/10/2014 |
10-Q
| Quarterly Report for the period ended August 31, 2014 |
| 08/26/2014 |
10-K
| Annual Report for the period ended May 31, 2014 |
| 06/03/2014 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Immucor Announces Lifting of FDA NOIR NORCROSS, Ga., June 2, 2014 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that the U.S. Food and Drug Administration has informed the Company that the Notice of Intent to Revoke has been lifted. “We take our commitment to quality very seriously,” stated William A. Hawkins, Immucor’s President and Chief Executive Officer. “The core of Immucor’s business is making sure that patients who need a blood transfusion are matched with the right donor unit. Our upmost concern is delivering quality products so patients receive the life-saving transfusions they need.” The NOIR, which was issued by the FDA in June 2009, was related to the Company’s Reagent Red Blood Cells and Anti-E Blood Grouping Reagent products ..." |
|
| 04/14/2014 |
10-Q
| Quarterly Report for the period ended February 28, 2014 |
| 01/13/2014 |
10-Q
| Quarterly Report for the period ended November 30, 2013 |
| 10/15/2013 |
10-Q
| Quarterly Report for the period ended August 31, 2013 |
| 08/26/2013 |
10-K
| Annual Report for the period ended May 31, 2013 |
| 08/12/2013 |
8-K
| Form 8-K - Current report |
| 04/12/2013 |
10-Q
| Quarterly Report for the period ended February 28, 2013 |
| 03/22/2013 |
8-K
| Form 8-K - Current report |
| 02/22/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Amended and Restated Amendment No. 2 to Amended and Restated Credit Agreement, by and among Immucor, Inc., IVD Intermediate Holdings B Inc., the Subsidiary Guarantor party thereto, CitiBank, N.A., as administrative agent, and certain other parties thereto (the “Credit Agreement”)",
"Amendment No. 3 to the Credit Agreement",
"Amendment No. 4 to the Credit Agreement" |
|
| 01/31/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/16/2013 |
8-K
| Form 8-K - Current report |
| 01/14/2013 |
10-Q
| Quarterly Report for the period ended November 30, 2012 |
|
|
|